Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p3
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 3/16)
Character Range: 126150–129002

containing 3 mg or less of benzydamine; or
 (c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.
BEPHENIUM SALTS.
BIFONAZOLE in preparations for dermal use except:
 (a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or
 (b) in preparations for the treatment of tinea pedis.
BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 20 mg bilastine for the treatment of adults and children aged 12 years and over.
BISACODYL in divided preparations for:
 (a) oral use except in a primary pack containing 20 dosage units or less containing 5 mg or less of bisacodyl per dosage unit; or
 (b) rectal use except:

          (i) in a primary pack containing 12 dosage units or less of suppositories containing 10 mg or less of bisacodyl per dosage unit; or

          (ii) in a primary pack containing 25 dosage units or less of enemas containing 10 mg or less of bisacodyl per dosage unit.
BRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine.
BROMHEXINE.
BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 (b) in a day‑night pack containing brompheniramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
 except in preparations for the treatment of children under 2 years of age.
BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
CARBETAPENTANE except in preparations containing 0.5% or less of carbetapentane.
CARBOCISTEINE.
CETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:
 (a) in a primary pack containing not more than 10 days' supply; and
 (b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
CHLOPHEDIANOL.
CHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol except in preparations containing 0.5% or less of chlorbutanol.
CHLOROFORM in preparations for therapeutic use except:
 (a) when included in Schedule 4; or
 (b) in preparations containing 0.5% or less of chloroform.
CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 (b) in a